Background Cancers with a defective DNA mismatch repair (dMMR) system contain
thousands of mutations most frequently located in monomorphic microsatellites and are …

Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …

Programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1)
interaction plays a crucial role in tumor-associated immune escape. Here, we verify that …

Breast cancer was traditionally not considered a particularly immunogenic tumor. However,
recent developments have shown that some aggressive triple-negative breast cancers are …

Purpose To evaluate the association between PD-L1 expression (PD-L1+) and
clinicopathological characteristics and effect on prognosis in primary breast cancer (PBC) …

Immunotherapy combined with chemotherapy has been demonstrated to be effective in
early triple-negative breast cancer (TNBC). In this single-arm, phase II study with Simon's …

Purpose: Conflicting data have been reported on the prognostic value of PD-L1 protein and
gene expression in breast cancer. Experimental Design: Medline, Embase, Cochrane …

Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are
associated with modest response rates as monotherapy in metastatic breast cancer, but are …

Abstract Treatment of immunologically cold tumors is a major challenge for immune
checkpoint inhibitors (ICIs). Interleukin 12 (IL‐12) can invigorate ICIs against cold tumors by …

The treatment of several solid and hematologic malignancies with immune checkpoint
inhibitors (against programmed death receptor-1/ligand-1 [PD-1/PD-L1]) has dramatically …